ACIU Company Profile and Key Details
AC Immune SA
ACIU Stock Price Chart
Stock Price Today
AC Immune SA (ACIU) stock declined over -0.38%, trading at $2.63 on NASDAQ, down from the previous close of $2.64. The stock opened at $2.63, fluctuating between $2.60 and $2.66 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Company Information
| Employees | 133 |
| Beta | 1.28 |
| Sales or Revenue | $14.80M |
| 5Y Sales Change% | 0.502% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
AC Immune SA (NASDAQ: ACIU) stock price is $2.63 in the last trading session. During the trading session, ACIU stock reached the peak price of $2.66 while $2.60 was the lowest point it dropped to. The percentage change in ACIU stock occurred in the recent session was -0.38% while the dollar amount for the price change in ACIU stock was -$0.01.
The NASDAQ listed ACIU is part of Biotechnology industry that operates in the broader Healthcare sector. AC Immune SA designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Judith Moore
Global Head of Communications
Mr. Christopher Roberts
Interim Chief Financial Officer & Vice President of Fin.
Prof. Johannes Rolf Streffer M.D.
Chief Medical Officer
Mr. Jean-Fabien Monin
Chief Admin. Officer
Mr. Julian Snow
Vice President of U.S. Fin. & Corporation Devel.
Dr. Andrea Pfeifer Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Alexandre Caratsch
Gen. Counsel
Dr. Marie Kosco-Vilbois
Chief Scientific Officer
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Mr. Howard Donovan
Chief HR Officer
ACIU's closing price is 17.33% higher than its 52-week low of $2.25 where as its distance from 52-week high of $4.98 is -46.97%.
Number of ACIU employees currently stands at 133.
Official Website of ACIU is: https://www.acimmune.com
ACIU could be contacted at phone 412 134 59121 and can also be accessed through its website. ACIU operates from Building B, Lausanne, 1015, Switzerland.
ACIU stock volume for the day was 57.69K shares. The average number of ACIU shares traded daily for last 3 months was 136.38K.
The market value of ACIU currently stands at $262.16M with its latest stock price at $2.63 and 99.68M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com